CN1294136C - 用于治疗的烟碱乙酰胆碱受体新型配体 - Google Patents

用于治疗的烟碱乙酰胆碱受体新型配体 Download PDF

Info

Publication number
CN1294136C
CN1294136C CNB028110498A CN02811049A CN1294136C CN 1294136 C CN1294136 C CN 1294136C CN B028110498 A CNB028110498 A CN B028110498A CN 02811049 A CN02811049 A CN 02811049A CN 1294136 C CN1294136 C CN 1294136C
Authority
CN
China
Prior art keywords
disease
treatment
application
illness
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028110498A
Other languages
English (en)
Chinese (zh)
Other versions
CN1512995A (zh
Inventor
E·菲利普斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1512995A publication Critical patent/CN1512995A/zh
Application granted granted Critical
Publication of CN1294136C publication Critical patent/CN1294136C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNB028110498A 2001-06-01 2002-05-29 用于治疗的烟碱乙酰胆碱受体新型配体 Expired - Fee Related CN1294136C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29520601P 2001-06-01 2001-06-01
US60/295,206 2001-06-01

Publications (2)

Publication Number Publication Date
CN1512995A CN1512995A (zh) 2004-07-14
CN1294136C true CN1294136C (zh) 2007-01-10

Family

ID=23136711

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028110498A Expired - Fee Related CN1294136C (zh) 2001-06-01 2002-05-29 用于治疗的烟碱乙酰胆碱受体新型配体

Country Status (18)

Country Link
EP (1) EP1397366B1 (enExample)
JP (1) JP2004532877A (enExample)
KR (1) KR20040003021A (enExample)
CN (1) CN1294136C (enExample)
AT (1) ATE353332T1 (enExample)
BR (1) BR0210075A (enExample)
CA (1) CA2455341A1 (enExample)
DE (1) DE60218032T2 (enExample)
DK (1) DK1397366T3 (enExample)
ES (1) ES2280538T3 (enExample)
IL (1) IL158735A0 (enExample)
MX (1) MXPA03010996A (enExample)
NO (1) NO20035333D0 (enExample)
NZ (1) NZ529426A (enExample)
PT (1) PT1397366E (enExample)
SI (1) SI1397366T1 (enExample)
WO (1) WO2002096912A1 (enExample)
ZA (1) ZA200308779B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
BR0309342A (pt) 2002-04-18 2005-02-15 Astrazeneca Ab Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
JP4523775B2 (ja) 2002-04-18 2010-08-11 アストラゼネカ・アクチエボラーグ 複素環化合物
BR0309343A (pt) * 2002-04-18 2005-02-15 Astrazeneca Ab Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
JP4855264B2 (ja) * 2003-10-21 2012-01-18 アストラゼネカ・アクチエボラーグ スピロフロピリジンアリール誘導体
TW200813067A (en) * 2006-05-17 2008-03-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
CA2728675A1 (en) 2008-06-20 2009-12-23 Astrazeneca Ab Dibenzothiazepine derivatives and use thereof
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
TWI519532B (zh) 2010-05-17 2016-02-01 艾維沃製藥公司 （Ｒ）－７－氯－Ｎ－（啶－３－基）苯並［b］噻吩－２－羧醯胺鹽酸鹽單水合物之結晶形體
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
RU2017136693A (ru) 2012-05-08 2019-02-08 Форум Фармасьютикалз, Инк. Способы поддержания, лечения или улучшения когнитивной функции
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
US9593106B2 (en) 2013-02-07 2017-03-14 Heptares Therapeutics Limited Piperidin-1-yl and azepin-1-yl carboxylates as muscarinic M4 receptor agonists
JP6401254B2 (ja) 2013-06-21 2018-10-10 武田薬品工業株式会社 プロキネシチン受容体のモジュレータとしての１−スルホニルピペリジン誘導体
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
GB202414197D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel compounds
GB202414193D0 (en) 2024-09-27 2024-11-13 Addex Pharmaceuticals Sa Novel compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999003859A1 (en) * 1997-07-18 1999-01-28 Astra Aktiebolag Novel spiroazabicyclic heterocyclic compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002500652A (ja) * 1997-05-30 2002-01-08 ニューロサーアチ・アクティーゼルスカブ スピロ−キヌクリジン誘導体、その製造方法及びその使用方法
SE9900100D0 (sv) * 1999-01-15 1999-01-15 Astra Ab New compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999003859A1 (en) * 1997-07-18 1999-01-28 Astra Aktiebolag Novel spiroazabicyclic heterocyclic compounds

Also Published As

Publication number Publication date
IL158735A0 (en) 2004-05-12
PT1397366E (pt) 2007-04-30
NO20035333D0 (no) 2003-11-28
MXPA03010996A (es) 2004-02-27
ZA200308779B (en) 2005-02-11
HK1063787A1 (en) 2005-01-14
BR0210075A (pt) 2004-08-17
CA2455341A1 (en) 2002-12-05
DE60218032D1 (de) 2007-03-22
DK1397366T3 (da) 2007-05-07
KR20040003021A (ko) 2004-01-07
EP1397366A1 (en) 2004-03-17
NZ529426A (en) 2005-07-29
ES2280538T3 (es) 2007-09-16
SI1397366T1 (sl) 2007-06-30
DE60218032T2 (de) 2007-08-16
EP1397366B1 (en) 2007-02-07
CN1512995A (zh) 2004-07-14
WO2002096912A1 (en) 2002-12-05
JP2004532877A (ja) 2004-10-28
ATE353332T1 (de) 2007-02-15

Similar Documents

Publication Publication Date Title
CN1512995A (zh) 用于治疗的烟碱乙酰胆碱受体新型配体
CN1325501C (zh) 杂环化合物
EP1213291B1 (en) Spiro [1-azabicyclo[2.2.2]octane-3,2'(3'H)-furo[2,3-b]pyridine for use in the treatment of psychotic and intellectual impairment disorders
US7001900B2 (en) Azabicyclic compounds for the treatment of disease
EP1425286B1 (en) Substituted 7-aza-[2.2.1]bicycloheptanes for the treatment of diseases
US6683090B1 (en) N-azabicyclo-amide derivatives
CN1325499C (zh) 噻吩基化合物
US6828330B2 (en) Quinuclidine-substituted hetero-bicyclic aromatic compounds for the treatment of disease
US20050209236A1 (en) Heteroaryl carboxylic acid amides
NZ331145A (en) Azabicyclic esters of carbamic acids useful in treating disorders involving reduced cholinergic function
US9867812B2 (en) N-biarylamides
US6569865B2 (en) Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
US20040147522A1 (en) Compounds having both alpha7 nicotinic agonist activity and 5HT3 antagonist activity for the treatment of CNS diseases
WO2002016356A2 (en) Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
WO2003087102A1 (en) Furyl compounds
EP1419162A1 (en) Substituted-aryl 7-aza 2.2.1]bicycloheptanes for the treatment of disease
US20070191422A1 (en) Nicotinic acetylcholine receptor ligands
US20070244097A1 (en) Nicotinic AcetylcholineReceptor Ligands
AU2002303064A1 (en) Novel ligand for nicotinic acetylcholine receptors useful in therapy
ZA200604018B (en) 4-Substituted imidazoles
HK1063787B (en) Novel ligand for nicotinic acetylcholine receptors useful in therapy
JP2007506723A (ja) 非アミド性ノナン
HK1079522B (en) Thienyl compounds

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee